AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8314294
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g cefuroxime i.v. injected 20 minutes after incision
Trial: 31623493
Drug: Pregabalin controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin controlled-release (CR) 165 and 330 mg/day
Trial: 26626148
Drug: Low-dose GTP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GTP (500 mg)
Trial: 26626148
Drug: High-dose GTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GTP (1,000 mg)
Trial: 26626148
Drug: GTP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTP treatment (both doses)
Trial: 23300343
Drug: Intravesical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical mitomycin C (MMC) 40 mg within 6 hours after TURBT
Trial: 9212308
Drug: Porcine insulin
RxNorm normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine insulin (P)
Trial: 8484622
Drug: Max‐EPA (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Max‐EPA (3.2 g/day eicosapentaenoic acid)
Trial: 29449506
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) 40 mg subcutaneously every other week for 6 weeks
Trial: 26910749
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dydrogesterone and hydroxyprogesterone caproate
Trial: 21246845
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment based on syndrome differentiation, using Ashi points and specific acupuncture points (Yanglingquan, Taichong, Zusanli)
Trial: 21246845
Drug: Muscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscular injection of Bucinnazine
Trial: 21246845
Drug: Medication (Bucinnazine)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Bucinnazine)
Trial: 18441320
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg > 6 h before CAG (group A)
Trial: 18441320
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg in the cath-lab after CAG only in case of PCI (group B)
Trial: 12063152
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day) for 50 weeks
Trial: 9734550
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day) for 38 weeks and then 12 weeks of placebo
Trial: 9734550
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day) for 14 weeks and then 36 weeks of placebo
Trial: 7925206
Drug: Rocuronium 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.75 mg kg‐1
Trial: 8556998
Drug: Rocuronium 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.9 mg kg‐1
Trial: 3287909
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg for two days
Trial: 3287909
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg for five days
Trial: 3287909
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg four times per day
Trial: 3287909
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg for one day
Trial: 16571878
Drug: 90 microg
RxNorm normalized name: Linaclotide 290 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 microg subvirion influenza A (H5N1) vaccine
Trial: 16571878
Drug: 45 microg
RxNorm normalized name: Linaclotide 145 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 microg subvirion influenza A (H5N1) vaccine
Trial: 16571878
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg subvirion influenza A (H5N1) vaccine
Trial: 16571878
Drug: 7.5 microg
RxNorm normalized name: Levonorgestrel 37.5 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 microg subvirion influenza A (H5N1) vaccine
Trial: 10681608
Drug: Calcipotriol cream
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol cream (50 microg/g) combined with twice weekly broad-band UVB
Trial: 9080870
Drug: Chloroquine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (5 mg base/kg, n = 20)
Trial: 9080870
Drug: Primaquine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (0.5 mg base/kg, n = 30)
Trial: 8442748
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy
Trial: 22333328
Drug: Naltrexone (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (oral, Revia)
Trial: 18600342
Drug: Harmonic Scalpel
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Harmonic Scalpel Group (HS-G)
Trial: 18600342
Drug: Clip-Ligation Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clip-Ligation Group (CL-G)
Trial: 16928842
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg tablets given twice daily
Trial: 16928842
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg extended-release tablets given once daily
Trial: 6990674
Drug: Cimetidine 600
RxNorm normalized name: cimetidine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 600 mg
Trial: 30807328
Drug: Oral Sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Sucrose
Trial: 26874258
Drug: Neostigmine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 40 μg.kg(‐1)
Trial: 26874258
Drug: Neostigmine 0
RxNorm normalized name: neostigmine 0.01 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0 μg.kg(‐1)
Trial: 26874258
Drug: Neostigmine 10
RxNorm normalized name: neostigmine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 10 μg.kg(‐1)
Trial: 26874258
Drug: Neostigmine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 20 μg.kg(‐1)
Trial: 12063831
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5‐FU and radiation
Trial: 9627274
Drug: Enalaprilat (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (0.5 mg bolus followed by incremental infusion up to 10 mg, mean 8.3 mg)
Trial: 2231061
Drug: Screening for
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening for oral cancer; no specific intervention details provided.
Trial: 362197
Drug: 10‐mg clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg clotrimazole buccal troches taken five times daily for two weeks
Trial: 362197
Drug: Placebo taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken five times daily for two weeks
Trial: 30958973
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.1 g·kg‐1·day‐1 of creatine + 0.1 g·kg‐1·day‐1 of maltodextrin) during 8 weeks of HVRT
Trial: 30958973
Drug: Placebo (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.2 g·kg‐1·day‐1 of maltodextrin) during 8 weeks of HVRT
Trial: 23334268
Drug: Local administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local administration of piperacillin/tazobactam
Trial: 10768702
Drug: Methadone hydrochloride
RxNorm normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone hydrochloride dose increase to 70 mg/d (n = 31 patients)
Trial: 10768702
Drug: Combined contingent
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined contingent vouchers and methadone dose increase (n = 32 patients)
Trial: 8808718
Drug: Lomefloxacin 400
RxNorm normalized name: lomefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin 400 mg once daily for 15 days
Trial: 8808718
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily for 15 days
Trial: 1425877
Drug: nalbuphine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine (0.2 mg.kg‐1 i.v.)
Trial: 4016785
Drug: Low-dose treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose treatment strategy (2 X 10(6) units/m2 daily for 28 days, then daily for 5 days every other week by im injection)
Trial: 4016785
Drug: High-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose treatment strategy (5 X 10(6) units/m2 by continuous iv infusion over 24 hours, escalating by 5 X 10(6) units/m2/day as tolerated over 10 days, repeated every 28 days)
Trial: 27796466
Drug: Netazepide 1
RxNorm normalized name: Netazepide
DrugBank: Netazepide (DB12355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netazepide 1 mg
Trial: 27796466
Drug: Netazepide 5
RxNorm normalized name: Netazepide
DrugBank: Netazepide (DB12355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netazepide 5 mg
Trial: 27796466
Drug: Netazepide 25
RxNorm normalized name: Netazepide
DrugBank: Netazepide (DB12355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netazepide 25 mg
Trial: 27796466
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg daily for 28 days
Trial: 23446906
Drug: High-protein (HP)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein (HP) breakfast (350-kcal, 35 g protein)
Trial: 23446906
Drug: Normal-protein (NP)
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-protein (NP) breakfast (350-kcal, 13 g protein)
Trial: 19326695
Drug: SPF 40
RxNorm normalized name: Solbar Shield Suncreen SPF 40
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPF 40 sunscreen cream containing ecamsule 3%, octocrylene 10%, avobenzone 2%, and titanium dioxide 5% (tetrad)
Trial: 19326695
Drug: Ecamsule-deprived cream
RxNorm normalized name: ecamsule
DrugBank: Ecamsule (DB09534)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ecamsule-deprived cream (triad-E)
Trial: 19326695
Drug: Avobenzone-deprived cream
RxNorm normalized name: Avobenzone
DrugBank: Avobenzone (DB09495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avobenzone-deprived cream (triad-A)
Trial: 16957433
Drug: Topical retapamulin
RxNorm normalized name: retapamulin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retapamulin ointment, 1% for 5 days twice daily
Trial: 16957433
Drug: Oral cephalexin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cephalexin, 500 mg twice daily for 10 days
Trial: 11703421
Drug: Metformin (MG)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MG)
Trial: 7536071
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide (LD-CY, 1500 mg/m2) plus cisplatin (CDDP) 100 mg/m2 (OvCa) or epirubicin (EPR) 120 mg/m2 (BrCa) plus recombinant human G-CSF (rhG-CSF)
Trial: 7536071
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with carboplatin 1200 mg/m2, etoposide 900 mg/m2 and melphalan 100 mg/m2 with reinfusion of PBSC
Trial: 3148298
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of human milk since the 15th day of TPN
Trial: 3148298
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole since the 15th day
Trial: 3148298
Drug: Parenteral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral antibiotic therapy for septicemia since the 1st day
Trial: 28736267
Drug: Gamma tocopherol
RxNorm normalized name: Gamma tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma tocopherol (γT) 1200 mg daily for 14 days
Trial: 21518073
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (n=85) received an educational session, dental supplies, and scheduled oral care appointment.
Trial: 8366188
Drug: famotidine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 2.5 mg
Trial: 8366188
Drug: famotidine 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 5.0 mg
Trial: 8366188
Drug: famotidine 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 10.0 mg
Trial: 8366188
Drug: famotidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 0.5 mg
Trial: 30276974
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with paclitaxel and cisplatin
Trial: 27483185
Drug: Monthly text
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly text message checking contact details (Control)
Trial: 15829782
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injection into the mid-belly of the muscle bulks (distal group)
Trial: 15829782
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A injection into the proximal part of both heads of the gastrocnemius (proximal group)
Trial: 12810404
Drug: MLCT diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLCT diet (14 g of MLCT containing 1.7 g MCFA daily at breakfast for 12 weeks)
Trial: 9795914
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg lamivudine once daily
Trial: 9795914
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lamivudine once daily
Trial: 83330
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rapid smoking and covert sensitization
Trial: 24172309
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g MCT oil/d
Trial: 24172309
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g corn oil/d
Trial: 19014838
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of clarithromycin extended-release 500-mg tablets under fasting conditions
Trial: 19014838
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of clarithromycin extended-release 500-mg tablets under fasting conditions
Trial: 19014838
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of clarithromycin extended-release 500-mg tablets under fed conditions
Trial: 19014838
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of clarithromycin extended-release 500-mg tablets under fed conditions
Trial: 16047460
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg twice daily
Trial: 9381885
Drug: Vaginal suppositories
RxNorm normalized name: Miconazole Nitrate Vaginal Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppositories of 'Zhlemik'
Trial: 2210463
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg four times daily)
Trial: 31751759
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) for hazelnut allergy for at least 6 months.
Trial: 31751759
Drug: Baseline eliciting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline eliciting dose of hazelnut protein was 106 mg (IQR, 51-249); after 6 months of OIT, it increased to 523 mg (IQR, 190-1635) (P < .0001).
Trial: 30341774
Drug: Topical regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical regorafenib (25 μl, 30 mg ml‐1) three times a day for 12 weeks
Trial: 30341774
Drug: Ocular treatment‐emergent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular treatment‐emergent adverse events (TEAEs)
Trial: 30341774
Drug: Rescue treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue treatment (intravitreal ranibizumab)
Trial: 25802037
Drug: Aerobic interval
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic interval training (AIT) for 12 weeks (three weekly sessions lasting 38 min with ≈ 16 min at 85‐90% of VO2peak)
Trial: 21383284
Drug: Fluorouracil and
RxNorm normalized name: Fluorouracil and salicylic acid only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil and folinic acid chemotherapy
Trial: 17255220
Drug: Dihydroartemisinin suppository
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin suppository (DHA)
Trial: 17255220
Drug: Intramuscular artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular artemether (ART)
Trial: 15472673
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of aqueous sodium phosphate (45 mL each)
Trial: 15472673
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of aqueous sodium phosphate
Trial: 15472673
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of aqueous sodium phosphate
Trial: 26485846
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical anal lignocaine ointment and local infiltration anesthesia (G2)
Trial: 17139644
Drug: Arthroscopic lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic lavage plus administration of corticosteroids (ALC)
Trial: 17139644
Drug: Joint aspiration
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint aspiration plus administration of corticosteroids (JAC)
Trial: 17139644
Drug: Arthroscopic lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic lavage plus administration of placebo (ALP)
Trial: 10750366
Drug: Argatroban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (10 mg intravenous drip infusion)
Trial: 1630802
Drug: Anti-HCV antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-HCV antibody positive patients in chronic haemodialysis
Trial: 17644412
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of KW-3902 (selective A1 adenosine receptor antagonist)
Trial: 16326292
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion plus 10 microg/kg of intrathecal morphine (ITM group, n = 23)
Trial: 16326292
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion alone (control group, n = 23)
Trial: 9817281
Drug: Standard-dose m-BACOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose m-BACOD plus GM-CSF
Trial: 819200
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in air with a modal tumour dose of 6000 rad in 24 fractions over approximately 5 weeks.
Trial: 819200
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in hyperbaric oxygen (3 atm) with a modal tumour dose of 6000 rad in 24 fractions over approximately 5 weeks.
Trial: 819200
Drug: Cumulative Radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cumulative Radiation Effect (CRE) analysis of treatment regimes.
Trial: 22863021
Drug: Rapid Syllable
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Syllable Transition Treatment